NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free CSBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.50▼$4.7750-Day Range$9.11▼$10.9652-Week Range$7.19▼$14.68Volume3,640 shsAverage Volume7,135 shsMarket Capitalization$61.43 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrends Get Champions Oncology alerts: Email Address Champions Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside65.9% Upside$7.50 Price TargetShort InterestBearish0.95% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment1.04Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector377th out of 923 stocksBiological Products, Except Diagnostic Industry54th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingChampions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.95% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Champions Oncology has recently increased by 5.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChampions Oncology has received a 71.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Champions Oncology is -0.81. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 12 news articles for Champions Oncology this week, compared to 12 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders45.69% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 13.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Champions Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMusk, Bezos, and Gates All On Board… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. About Champions Oncology Stock (NASDAQ:CSBR)Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Read More Ad Porter & CompanyMusk, Bezos, and Gates All On Board… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. CSBR Stock News HeadlinesMay 26 at 8:11 AM | nytimes.comBarcelona’s Champions League win felt like a shift in power — but Lyon insist they will be backMay 26 at 3:10 AM | msn.comBarcelona beat Lyon 2-0 to win second straight Women's Champions LeagueMay 25 at 10:09 PM | msn.comBarcelona finally beats Lyon and retains Women’s Champions League crownMay 25 at 5:09 PM | msn.comBarcelona beats Lyon to win a third Women’s Champions League title in four yearsMay 25 at 5:09 PM | barrons.comToulouse Outlast Leinster In Champions Cup Final ThrillerMay 25 at 12:08 PM | msn.comLeinster coach Jacques Nienaber exploits loophole to be a water boy in Champions Cup finalMay 25 at 7:07 AM | msn.comWho has won the most UEFA Women's Champions League titles? All-time list of winners, most successful teams and playersMay 24 at 2:30 PM | msn.comHegerberg set to play for Lyon in Women's Champions League final after injuryMay 24 at 7:53 AM | msn.comHummels: Champions League final demands special emotional preparationMay 23 at 9:52 PM | msn.comYokohama takes a 2-1 lead into the 2nd leg of the Asian Champions League final against Al-AinMay 21, 2024 | finance.yahoo.comChampions Oncology (NASDAQ:CSBR) shareholders have endured a 53% loss from investing in the stock three years agoMay 16, 2024 | finance.yahoo.comChampions Oncology Inc (2I3.SG)May 10, 2024 | barrons.comCrespo Relishing Kewell Reunion In Asian Champions League FinalMay 9, 2024 | msn.comFrom fan to hero, super sub Joselu lifts Real Madrid past Bayern and into Champions League finalMay 9, 2024 | msn.comBayern offside is latest Champions League controversy for ref Marciniak after cup final successesMay 9, 2024 | msn.comInevitable Madrid continue Champions League love affairMay 9, 2024 | msn.comDavid Alaba recreates viral chair celebration as Real Madrid reach Champions League finalMay 9, 2024 | msn.comJourneyman Joselu takes long and winding road to Champions League finalMay 9, 2024 | msn.comWay too early questions for Champions League final as Real Madrid face Borussia Dortmund at WembleyMay 9, 2024 | msn.comChampions League final prediction: Real Madrid vs. Dortmund odds, expert picks for 2024 match at WembleyMay 8, 2024 | msn.comReal Madrid-Bayern Munich UEFA Champions League semifinal ends with controversyMay 8, 2024 | msn.comReal Madrid rallies late to beat Bayern 2-1 and reach another Champions League finalMay 8, 2024 | msn.comChampions League matchday blog: Real Madrid vs. BayernMay 8, 2024 | msn.com‘Nobody expected this’: Borussia Dortmund stuns PSG to reach Champions League finalMay 6, 2024 | barrons.comLyon Win Seven-goal Thriller To Damage Lille Champions League HopesSee More Headlines Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/26/2024Next Earnings (Estimated)7/22/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CSBR CUSIPN/A CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$7.50 Low Stock Price Target$7.50 Potential Upside/Downside+65.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net Margins-19.76% Pretax Margin-19.62% Return on Equity-850.72% Return on Assets-32.62% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual Sales$53.87 million Price / Sales1.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book13.29Miscellaneous Outstanding Shares13,590,000Free Float7,383,000Market Cap$61.43 million OptionableOptionable Beta0.40 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesRonnie MorrisPresident Chief Executive Officer & DirectorDavid Barry MillerChief Financial OfficerKarin Abarca HeidemannVice President-Scientific OperationsMichael RitchieChief Commercial OfficerMaria ManciniVice President-PharmacologyKey CompetitorsMetagenomiNASDAQ:MGXZura BioNASDAQ:ZURAInnate PharmaNASDAQ:IPHACandel TherapeuticsNASDAQ:CADLInvivydNASDAQ:IVVDView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Bought 12,380 shares on 4/26/2024Ownership: 0.091%Daniel Newman MendelsonBought 1,000 shares on 1/12/2024Total: $6,500.00 ($6.50/share)Daniel Newman MendelsonBought 2,944 shares on 1/10/2024Total: $18,576.64 ($6.31/share)Daniel Newman MendelsonBought 1,000 shares on 1/8/2024Total: $6,150.00 ($6.15/share)Daniel Newman MendelsonBought 2,000 shares on 1/5/2024Total: $12,180.00 ($6.09/share)View All Insider TransactionsView All Institutional Transactions CSBR Stock Analysis - Frequently Asked Questions Should I buy or sell Champions Oncology stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CSBR shares. View CSBR analyst ratings or view top-rated stocks. What is Champions Oncology's stock price target for 2024? 2 equities research analysts have issued 12 month price targets for Champions Oncology's stock. Their CSBR share price targets range from $7.50 to $7.50. On average, they anticipate the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 65.9% from the stock's current price. View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts. When is Champions Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our CSBR earnings forecast. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its earnings results on Tuesday, March, 12th. The biotechnology company reported ($0.19) earnings per share for the quarter. The biotechnology company earned $12.02 million during the quarter. Champions Oncology had a negative trailing twelve-month return on equity of 850.72% and a negative net margin of 19.76%. What is Ronnie Morris' approval rating as Champions Oncology's CEO? 8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL). Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Newman Mendelson and Ronnie Morris. View institutional ownership trends. This page (NASDAQ:CSBR) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsMusk, Bezos, and Gates All On Board… Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsBiden replacement revealed?Paradigm PressNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.